electroCore Expands Intellectual Patent Portfolio for nVNS Technology
16 Fevereiro 2023 - 10:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced that the United
States Patent and Trademark Office (USPTO) has issued two patents
and intends to issue a third new patent related to its non-invasive
vagus nerve stimulation (nVNS) technology to electroCore, including
the following patents:
- U.S. Patent No. 11,534,600 entitled “Non-Invasive Nerve
Stimulation to Treat or Prevent Autism Spectrum Disorders and Other
Disorders of Psychological Development” issued on December 27,
2022. This patent is generally related to devices and methods for
treating behavioral disorders, such as
attention-deficit/hyperactivity disorder (ADHD), autism spectrum
disorder and Asperger syndrome with nVNS by applying an electrical
impulse having bursts of 2-20 pulses and a frequency of 1 to 100
Hz.
- U.S. Patent No. 11,581,090 entitled “Technologies for Initial
Provisioning and Refilling of Medical Devices” issued on February
14, 2023. This patent is generally related to electrical
stimulation devices that limit the use of the devices to a
prescribed number of treatments (e.g., doses) and/or a prescribed
time period.
- U.S. Patent No. 11,590,341 entitled “Vagal Nerve Stimulation
Therapy” to be issued on February 28, 2023. This patent is
generally related to a method of treating post-operative symptoms
in a patient that includes attaching a patch to the neck of the
patient and wirelessly transmitting electrical impulses to
electrodes in the patch to reduce intraperitoneal or
retroperitoneal inflammation. The electrical impulses are applied
for at least two doses/per day with each dose having a duration of
60 seconds to 5 minutes.
“We are excited to broaden our intellectual property with the
addition of these new patents” stated Dan Goldberger, Chief
Executive Officer of electroCore. “electroCore’s proven technology
and expanding intellectual property highlights its use across a
range of disorders and diseases. We are excited to begin exploring
the behavioral disorder space and the potential for nVNS in a
post-operative setting.”
About electroCore, Inc. electroCore, Inc. is a
commercial stage bioelectronic company dedicated to improving
outcomes through its non-invasive vagus nerve stimulation (“nVNS”)
technology platform. Our focus is the commercialization of medical
devices for the management and treatment of certain medical
conditions and consumer product offerings utilizing nVNS to promote
general wellbeing and human performance in the United States and
select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to,
statements regarding electroCore's business prospects, the results
from investigator-initiated trials, its sales and marketing and
product development plans, future cash flow projections,
anticipated costs, its product portfolio or potential markets for
its technologies, the availability and impact of payor coverage,
the potential of nVNS generally, and other statements that are not
historical in nature, particularly those using terminology such as
"anticipates," "expects," "believes," "intends," other words of
similar meaning, derivations of such words and the use of future
dates. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to obtain additional financing
necessary to continue electroCore's business, sales and marketing
and product development plans, the uncertainties inherent in the
development of new products or technologies, the ability to
successfully commercialize our products, competition in the
industry in which electroCore operates and general market
conditions. All forward-looking statements are made as of the date
of this press release, and electroCore undertakes no obligation to
update forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should refer to all information set forth in this document and
should also refer to the disclosure of risk factors set forth in
the reports and other documents electroCore files with the SEC,
available at www.sec.gov.
Investors: Rich Cockrell CG Capital
404-736-3838 ecor@cg.capital
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024